Congenital cytomegalovirus (CMV) infection causes auditory, cognitive and neurologic impairment in thousands of infants each year in the United States. Recognition of infection in pregnant women is difficult because CMV often produces few symptoms, and antiviral treatment during pregnancy may have toxic effects. Could a new experimental vaccine hold the key to preventing maternal CMV infection during pregnancy and decrease the incidence of congenital CMV infection and its sequelae? Host Dr. Jennifer Shu evaluates the progress toward a CMV vaccine with Dr. Robert Pass, professor of pediatrics and microbiology at the University of Alabama at Birmingham School of Medicine. Dr. Pass also explains the proposed mechanism of action for the vaccine.
A Vaccine to Reduce Congenital CMV and Sequelae
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Congenital cytomegalovirus (CMV) infection causes auditory, cognitive and neurologic impairment in thousands of infants each year in the United States. Recognition of infection in pregnant women is difficult because CMV often produces few symptoms, and antiviral treatment during pregnancy may have toxic effects. Could a new experimental vaccine hold the key to preventing maternal CMV infection during pregnancy and decrease the incidence of congenital CMV infection and its sequelae? Host Dr. Jennifer Shu evaluates the progress toward a CMV vaccine with Dr. Robert Pass, professor of pediatrics and microbiology at the University of Alabama at Birmingham School of Medicine. Dr. Pass also explains the proposed mechanism of action for the vaccine.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Updates From the 7th World Symposium Task Force
HF Management for Patients with Comorbid Conditions
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
First-line Chemotherapy Options in Metastatic PDAC
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?